| Size | Price | Stock | Qty |
|---|---|---|---|
| 100g |
|
||
| 200g |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Sulfacetamide Sodium targets bacterial dihydropteroate synthase (DHPS), an enzyme involved in the synthesis of dihydrofolic acid. By inhibiting this enzyme, it blocks the synthesis of folic acid, which is essential for bacterial growth and replication. It is a competitive inhibitor of bacterial para-aminobenzoic acid (PABA).
|
|---|---|
| ln Vitro |
Sulfacetamide is a sulfonamide antibiotic. Sulfacetamide is able to inhibit the growth of all isolated strains. Depending on the type of bacteria concentrations of 0.006 up to 6.4% sodium sulfacetamide proved to be effective. Simultaneously, all patients were treated with sulfacetamide containing ointment and/or eye drops 4 times daily for maximum of 14 days. With swabs taken at intervals of 7 and 14 days no bacterial growth was detected. Sulfacetamide 10% topical lotion, sold under the brand name Klaron or Ovace, is approved for the treatment of acne and seborrheic dermatitis. Sulfacetamide has been investigated for use in the treatment of pityriasis versicolor and rosacea. It may also have anti-inflammatory properties when used to treat blepharitis or conjunctivitis. It is believed to work by limiting the presence of folic acid which bacteria need to survive. It has been suggested that sulfacetamide may also serve as a treatment for mild forms of hidradenitis suppurativa. Sulfacetamide has antibacterial activity and is used to control acne. Some research indicates that sulfacetamide derivatives may act as antifungals by an CYP51A1-independent mechanism
In vitro, Sulfacetamide Sodium inhibits the growth of various bacterial isolates. Its antibacterial activity is measured by determining the minimum inhibitory concentration (MIC) against susceptible organisms. It inhibits dihydropteroate synthase with an IC50 of 9.6 µM. |
| ln Vivo |
In vivo, Sulfacetamide Sodium is effective as a topical agent for skin and eye infections, and as an oral agent for urinary tract infections. Its efficacy is based on its local or systemic antibacterial activity. It is often used in combination with sulfur for a synergistic effect in the management of inflammatory facial dermatoses.
|
| Enzyme Assay |
In vitro assays measure the compound's ability to inhibit purified dihydropteroate synthase. The IC50 is determined by assessing the enzyme's activity in the presence of various concentrations of the compound.
|
| Cell Assay |
The antibacterial activity of Sulfacetamide Sodium is assessed in vitro by broth dilution or disk diffusion methods. The MIC against a panel of bacterial strains is determined to establish its spectrum of activity.
|
| Animal Protocol |
In vivo efficacy in animal models of infection would be used to evaluate the compound's therapeutic potential. However, its established clinical use for topical and urinary tract infections provides substantial evidence of in vivo activity.
|
| ADME/Pharmacokinetics |
Pharmacokinetic studies would characterize the absorption, distribution, metabolism, and excretion of Sulfacetamide Sodium. For topical use, local absorption is a key parameter. For oral use, systemic exposure is important.
|
| Toxicity/Toxicokinetics |
Toxicity studies would assess the safety profile of Sulfacetamide Sodium. As a sulfonamide, its potential for hypersensitivity reactions, crystalluria, and other adverse effects would be evaluated.
|
| References |
Langmuir.2016 Aug 9;32(31):7814-20.
|
| Additional Infomation |
Anhydrous sulfacetyl sodium is an organosodium salt, the monosodium salt of sulfacetyl. It is an EC 2.5.1.15 (dihydropteroate synthase) inhibitor with antibacterial and anti-infective activity. It contains a sulfacetyl (1-) group. Sulfacetyl sodium is the sodium salt form of sulfacetyl, a synthetic sulfonylacetamide derivative with antibacterial activity. Sulfacetyl inhibits bacterial folic acid synthesis by competing with p-aminobenzoic acid. It has broad-spectrum antibacterial activity and can be used as a topical anti-infective agent for the treatment of skin infections and as an oral medication for the treatment of urinary tract infections. (NCI04) An antibacterial agent used for the topical treatment of skin infections and the oral treatment of urinary tract infections. See also: Sulfacetyl sodium (note moved to).
Sulfacetamide Sodium is a well-established antibiotic. It is often used in combination with sulfur for a synergistic effect in the management of inflammatory facial dermatoses. It is also known as sodium sulfacetamide. |
| Molecular Formula |
C8H10N2O3S.NA
|
|
|---|---|---|
| Molecular Weight |
236.22
|
|
| Exact Mass |
236.023
|
|
| CAS # |
127-56-0
|
|
| Related CAS # |
Sulfacetamide sodium monohydrate;6209-17-2
|
|
| PubChem CID |
4022878
|
|
| Appearance |
White to off-white solid powder
|
|
| Boiling Point |
450.8ºC at 760 mmHg
|
|
| Flash Point |
226.4ºC
|
|
| LogP |
1.932
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
5
|
|
| Rotatable Bond Count |
2
|
|
| Heavy Atom Count |
15
|
|
| Complexity |
304
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
S(C1C([H])=C([H])C(=C([H])C=1[H])N([H])[H])([N-]C(C([H])([H])[H])=O)(=O)=O.[Na+]
|
|
| InChi Key |
PQMSFAORUFMASU-UHFFFAOYSA-M
|
|
| InChi Code |
InChI=1S/C8H10N2O3S.Na/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8;/h2-5H,9H2,1H3,(H,10,11);/q;+1/p-1
|
|
| Chemical Name |
sodium;acetyl-(4-aminophenyl)sulfonylazanide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.58 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.58 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.58 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 110 mg/mL (465.67 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2333 mL | 21.1667 mL | 42.3334 mL | |
| 5 mM | 0.8467 mL | 4.2333 mL | 8.4667 mL | |
| 10 mM | 0.4233 mL | 2.1167 mL | 4.2333 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA